Ratings Aarti Drugs Limited NSE India S.E.

Equities

AARTIDRUGS

INE767A01016

Market Closed - NSE India S.E. Other stock markets 05:13:52 27/06/2024 pm IST			5-day change	1st Jan Change
503.6 ^INR	-1.82%		-3.43%	+2.93%

18/06	Aarti Drugs Reports Fire Incident at Tarapur, India Unit	MT
06/05	Transcript : Aarti Drugs Limited, Q4 2024 Earnings Call, May 06, 2024

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

Over the past twelve months, analysts' opinions have been strongly revised upwards.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The company benefits from high valuations in earnings multiples.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is highly valued given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Revenue estimates are regularly revised downwards for the current and coming years.
For the past year, analysts have significantly revised downwards their profit estimates.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
AARTI DRUGS LIMITED	+2.93%	56Cr	-
ELI LILLY AND COMPANY	+55.09%	81TCr	C+
NOVO NORDISK A/S	+43.73%	64TCr	B
JOHNSON & JOHNSON	-6.51%	35TCr	C+
MERCK & CO., INC.	+19.31%	33TCr	B-
ABBVIE INC.	+9.83%	30TCr	C+
ASTRAZENECA PLC	+17.39%	25TCr	B+
ROCHE HOLDING AG	+2.62%	22TCr	A+
NOVARTIS AG	+12.94%	22TCr	B-
AMGEN INC.	+9.19%	17TCr	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes